Healthtech funding in H2 2025
European Healthtech startup funding raised during H2 2025.
In H2 2025, 198 European Healthtech companies closed 200 funding rounds and raised €3.5B in equity funding (excluding debt and grants), up 23.5% versus H2 2024. Debt rounds added €126M. UK led by capital raised, and YZR Capital was the most active investor. Data as of 20 Nov 2026.
Equity funding
€3.5B
+23.5% vs H2 2024 · excl. debt & grants · +€126M debt
Funding rounds
200
-1.0% vs H2 2024
Companies
198
Top country
UK
Rank among sectors
#5
9.6% of sector funding
Debt financing
€126M
3.4% of total
Top-10 round share
52.6%
of disclosed capital
Rounds ≥ €100M
5
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H2 2025 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jul | €420M | 43 |
| Aug | €514M | 23 |
| Sep | €537M | 44 |
| Oct | €1.7B | 47 |
| Nov | €442M | 26 |
| Dec | €128M | 17 |
Top countries
by € raisedHealthtech — top countries by capital, H2 2025 — interactive chart.
Data table
| Healthtech — top countries by capital, H2 2025 | |
|---|---|
| UK | €864M |
| Finland | €787M |
| Germany | €629M |
| Switzerland | €488M |
| Spain | €146M |
| Netherlands | €144M |
| France | €128M |
| Ireland | €125M |
Stage mix
by € raisedHealthtech — stage mix, H2 2025 — interactive chart.
Data table
| Healthtech — stage mix, H2 2025 | |
|---|---|
| Series D+ | €1.1B |
| Other | €919M |
| Series A | €531M |
| Series B | €451M |
| Series C | €366M |
| Seed | €143M |
| Debt | €126M |
| Grant | €58M |
| Growth/Late | €24M |
| Pre-Seed | €19M |
Exits & M&A
15 Acquisition · 1 IPO16 exits · €9.3B disclosed.
| Merus | Acquisition | Sep 2025 | €6.8B |
| Vicebio | Acquisition | Jul 2025 | €1.4B |
| Imcheck Therapeutics | Acquisition | Oct 2025 | €1.0B |
| Pharvaris | IPO | Jul 2025 | €172M |
Top deals
largest disclosed rounds in H2 2025| Company | Stage | Date | Amount |
|---|---|---|---|
| Oura Health | Series D+ | Oct 2025 | €774M |
| Tubulis Technologies | Series C | Oct 2025 | €308M |
| Ortivity | Other | Aug 2025 | €200M |
| DistalMotion | Series D+ | Nov 2025 | €130M |
| Oculis | Debt | Aug 2025 | €106M |
| Artios | Series D+ | Nov 2025 | €99M |
| CoMind | Series A | Oct 2025 | €86M |
| NUCLIDIUM | Series B | Jul 2025 | €84M |
| NanoPhoria | Series A | Oct 2025 | €84M |
| Trogenix | Series A | Oct 2025 | €80M |
| ViCentra | Series D+ | Sep 2025 | €73M |
| ProVerum | Series B | Aug 2025 | €68M |
| NRG Therapeutics | Series B | Sep 2025 | €58M |
| MRM Health | Series B | Sep 2025 | €55M |
| AMSilk | Other | Sep 2025 | €52M |
Top investors
most active in H2 2025, by deal count- YZR Capital6 deals
- Bpifrance5 deals
- EQT Life Sciences5 deals
- new investors5 deals
- Sofinnova Partners5 deals
- Bayern Kapital4 deals
- LocalGlobe4 deals
- Venture Kick4 deals
- Angelini Ventures3 deals
- BGF3 deals